Life changing bowel cancer treatment added to PBS benefitting thousands of Australians
4 March, 2022

The Royal College of Pathologists of Australasia (RCPA) supports the move to add Braftovi, a targeted therapy for metastatic colorectal cancer (mCRC) to the Pharmaceutical Benefits Schedule (PBS) this year, improving health outcomes for potentially thousands of patients in Australia.

Go Back

Page last updated:

Copyright © 2022 RCPA. All rights reserved.